Raman Singh Of Mundipharma Sets Sights On Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Mundipharma is squarely focused on emerging markets with Singapore at the center of its plans in Asia – and around the world – to increase sales in countries where it has scant presence in the prescription drug business and faces long lead times and regulatory hurdles to entry.
You may also be interested in...
Mundipharma has once again reinforced its partnership with Infinity by committing an additional $50 million to the partnership, with the money to be used in 2013 to support the biotech’s ongoing development of Hedgehog pathway inhibitor IPI-926.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.